This study is looking at cardiac sarcoidosis, which is a condition where small collections of inflammatory cells form in the heart muscle. Sarcoidosis is a disease that can affect different parts of the body, and when it involves the heart, it can cause problems with how the heart works. The study will use a substance called [68Ga]Ga-PentixaFor, which is given as an injection into a vein. This substance contains gallium-68 and pentixafor, and it is used together with a special imaging test called positron emission tomography combined with computed tomography, or PET/CT for short. This imaging method creates detailed pictures of the inside of the body and can help doctors see areas of inflammation in the heart.

The purpose of the study is to check how well 68Ga-Pentixafor PET/CT can detect cardiac sarcoidosis. The results from this new scan will be compared to another scan called 18F-FDG PET/CT, which is already used in regular medical practice to look for this condition. The study will involve patients who have sarcoidosis in other parts of their body and who are suspected of having or already have cardiac sarcoidosis. These patients will receive the 68Ga-Pentixafor injection and undergo the PET/CT scan in addition to their regular 18F-FDG scan.

During the study, doctors will look at the scan images to see if and where the 68Ga-Pentixafor is taken up in the heart muscle. They will measure how much of the substance appears in different areas and describe the pattern of uptake, whether it appears in small spots or spread throughout the heart. The images will be examined by experienced doctors who will compare their findings. The study will also check if the substance shows up in other organs that might be affected by sarcoidosis and will look at how the substance moves through the body over time.